ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Cash Flow from Operations : HK$-402.02 Mil (TTM As of Dec. 2023)

ImmuneOnco Biopharmaceuticals (Shanghai) Cash Flow from Operations Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

ImmuneOnco Biopharmaceuticals (Shanghai)'s Cash Flow from Operations for the quarter that ended in Dec. 2023 is:

Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-402.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

ImmuneOnco Biopharmaceuticals (Shanghai)'s net income from continuing operations for the six months ended in Dec. 2023 was HK$-228.19 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

ImmuneOnco Biopharmaceuticals (Shanghai)'s depreciation, depletion and amortization for the six months ended in Dec. 2023 was HK$12.35 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

ImmuneOnco Biopharmaceuticals (Shanghai)'s change in working capital for the six months ended in Dec. 2023 was HK$-74.18 Mil. It means ImmuneOnco Biopharmaceuticals (Shanghai)'s working capital declined by HK$74.18 Mil from Jun. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

ImmuneOnco Biopharmaceuticals (Shanghai)'s cash flow from deferred tax for the six months ended in Dec. 2023 was HK$0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

ImmuneOnco Biopharmaceuticals (Shanghai)'s cash from discontinued operating Activities for the six months ended in Dec. 2023 was HK$0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

ImmuneOnco Biopharmaceuticals (Shanghai)'s asset impairment charge for the six months ended in Dec. 2023 was HK$0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

ImmuneOnco Biopharmaceuticals (Shanghai)'s stock based compensation for the six months ended in Dec. 2023 was HK$32.86 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

ImmuneOnco Biopharmaceuticals (Shanghai)'s cash flow from others for the six months ended in Dec. 2023 was HK$-0.09 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description